The healthcare debate is not winnable for any political candidate as it is highly complicated and involves significant costs no matter which way one goes. Based on the last Democratic political debate I think that the Affordable Care Act program should be re-worked vs. introducing an expensive Medicare for all program. Medicare could be revised to cover the 60-64 age group if this is affordable.
Predictably the www.biotech-wars.com will continue for a long time, especially when you add in all the current opioid litigations. And politicos continue to see the biotech sector as easy targets in an effort to gain votes and win elections.
There is no doubt that Johnson & Johnson remains the biggest target for lawyers and politicos. Below is an assessment of Johnson & Johnson’s situation from one of the people I follow on Seeking Alpha - Out of Ignorance the article paints a very bleak picture for (JNJ). Basically, the writer is concluding that Johnson & Johnson will be a legal target for many years and also writes “JNJ can expect bad headlines in abundance as the years unfold”. And I do agree with the writer’s comment “My prognosis for JNJ shareholders is prolonged discomfort.” I think this comment would apply to all biotech investments.
It is time for all biotech companies, and not just for (JNJ), to take counteroffensive measures.
It remains my view that politicos have made a massive mistake vilifying the biotech sector. There could be significant R&D/product development shifts away from America based on the anti-biotech sentiment that currently exists.
Unfortunately, I also see that the Biotech-Wars™ are now expanding towards both Tech-Wars and Class-Wars as politicos see additional voting gains attacking larger highly successful tech companies, especially Google, Facebook, Amazon, and Apple and wealthy Americans. The political vilification of successful American tech companies and wealthy Americans is troubling.
In the face of all of this negative political commentary, biotech companies continue to make remarkable success with new products and new meds. Below are articles from just a few days in September 2019 highlighting noteworthy biotech news and achievements;
National Lipid Association's New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins
bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (NASDAQ:CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress
In a year that the biotech sector has been totally maligned by politicos, biotech companies will again achieve outstanding medical success as they did in 2018. I remain 100% invested in biotech and medtech companies as of 9/18/2019. And I remain long (JNJ).
Respectfully submitted to Seeking Alpha on 9/18/2019.
Disclosure: I am/we are long ABBV, AZN, AMGN, BMY, PFE, MRK, LLY, CELG, MDT, RHHBY, JNJ.